| Mrs Josie C Dumond, NP-C | |
|
358 W Main St, Avon, CT 06001-3643 | |
| (860) 678-8605 | |
| Not Available |
| Full Name | Mrs Josie C Dumond |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 358 W Main St, Avon, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548873177 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 8009 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rockville General Hospital | Rockville, CT | Hospital |
| Manchester Memorial Hospital | Manchester, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Obgyn Group Of Eastern Connecticut Pc | 2769370352 | 10 |
News Archive
The UK's oldest national tri-service charity, in partnership with Northumbria University has today announced the launch of a programme of research into financial hardship and food poverty within the Armed Forces Community.
Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early.
Challenging risk assessment methods used for decades by toxicologists, a new review of the literature led by environmental health scientist Laura Vandenberg at the University of Massachusetts Amherst suggests that oral gavage, the most widely accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life.
Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 4 days ago
| Entity Name | Obgyn Group Of Eastern Connecticut Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376756908 PECOS PAC ID: 2769370352 Enrollment ID: O20040305000770 |
News Archive
The UK's oldest national tri-service charity, in partnership with Northumbria University has today announced the launch of a programme of research into financial hardship and food poverty within the Armed Forces Community.
Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early.
Challenging risk assessment methods used for decades by toxicologists, a new review of the literature led by environmental health scientist Laura Vandenberg at the University of Massachusetts Amherst suggests that oral gavage, the most widely accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life.
Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Josie C Dumond, NP-C 44 Cherry Hill Dr, Newington, CT 06111-1006 Ph: (860) 593-9384 | Mrs Josie C Dumond, NP-C 358 W Main St, Avon, CT 06001-3643 Ph: (860) 678-8605 |
News Archive
The UK's oldest national tri-service charity, in partnership with Northumbria University has today announced the launch of a programme of research into financial hardship and food poverty within the Armed Forces Community.
Pancreatic cancer has one of the highest mortality rates of any of the major cancers, and of the 43,000-plus Americans diagnosed with the disease each year, more than 94 percent die within five years of diagnosis. One reason for this high number of deaths is a lack of effective screening tools for catching the disease early.
Challenging risk assessment methods used for decades by toxicologists, a new review of the literature led by environmental health scientist Laura Vandenberg at the University of Massachusetts Amherst suggests that oral gavage, the most widely accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life.
Oncolytics Biotech Inc. , currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study.
Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.
› Verified 4 days ago
Sasha Perry, PMHNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 21 Waterville Rd, Avon, CT 06001 Phone: 860-284-0182 | |
Deborah L Collins-perrica, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 21 Waterville Rd, Avon, CT 06001 Phone: 860-284-0182 Fax: 860-284-6804 | |
Latonya Sheriee King, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 152 Simsbury Rd Bldg 9, Avon, CT 06001 Phone: 802-565-1755 Fax: 860-650-1920 | |
Courtney Streeto, APRN Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 21 Waterville Rd, Avon, CT 06001 Phone: 860-284-0182 | |
Marjorie Arni, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 21 Waterville Rd, Avon, CT 06001 Phone: 860-674-2691 Fax: 860-677-6443 | |
Mr. David Yarbrough, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 385 W Main St, Avon, CT 06001 Phone: 860-777-1280 | |
Debra Anne Gage, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 80 Fisher Drive, Hartford Hospital Cancer Center, Avon, CT 06001 Phone: 860-674-0088 |